Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06387381 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. 2 versions Re-verified since May 20, 2024, no change to tracked fieldsv3-v4
  2. Start date: May 1, 2024 to May 20, 2024v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA/FAP positive diseases.
Trial Details
NCT Number NCT06387381
Lead Sponsor First Affiliated Hospital of Chongqing Medical University
Conditions PSMA, FAP, Positron-Emission Tomography
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov